6-8
Oct
2026
CPHI Milan 2026
Fiera Milano, Italy
8L43
23-25
Nov
2026
CPHI India 2026
IICC, Yashobhoomi, Dwarka, Delhi
2D44

Eurofins

About Eurofins

Eurofins CDMO India provides comprehensive process development and manufacturing of small molecule drug substances and regulatory starting materials for preclinical and clinical supply, ensuring quality and safety. Contact: [email protected]
Eurofins BioPharma Product Testing offers complete CMC testing services including starting materials, intermediates, drug substances, drug products, packaging, and manufacturing support through broad technical expertise. Contact: [email protected]
Eurofins Assurance delivers GxP audit services. Contact: [email protected]

Certifications

Meet us at

  • CPHI Milan 2026

    Fiera Milano, Italy
    6 Oct 2026 - 8 Oct 2026
  • CPHI India 2026

    IICC, Yashobhoomi, Dwarka, Delhi
    23 Nov 2026 - 25 Nov 2026
  • Country/Region:
    India
  • On CPHI since:
    2022
  • Certificates:
    2
  • Employees:
    500 - 999
Company types
CMO/CDMO
Contract Research Organisation (CRO)
Contract Service
Primary activities
Analytical Services
Contract Manufacturer
Contract Research Organisation
Custom Manufacturing/Custom Synthesis
Intermediates Manufacturer
Contact info

Eurofins Resources (2)

  • Brochure Eurofins CDMO India

    Eurofins CDMO India offers services to advance and accelerate your process development and manufacturing requirements. We are known for our reliable and high-quality services in route scouting, process development, analytical method development and manufacturing of drug substance for tox, clinical studies and commercial use. Our brochure has details of our services 
  • Video Eurofins CDMO India

    Eurofins CDMO India, is your dedicated partner to accelerating your drug substance journey, from early-phase development to commercial supply. We offer a complete suite of services designed to streamline your process development & manufacturing needs:
    1. Expert synthesis, process development, and scale-up for preclinical studies
    2. Comprehensive analytical development and robust stability-indicating studies
    3. GMP/nGMP manufacturing of drug substance and specialty chemicals